PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE Drug Patent Profile

When do Promethazine Hydrochloride, Phenylephrine Hydrochloride W/codeine Phosphate patents expire, and what generic alternatives are available?

Promethazine Hydrochloride, Phenylephrine Hydrochloride W/codeine Phosphate is a drug marketed by Hikma and is included in one NDA.

The generic ingredient in PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE is codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride profile page.

Summary for PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	1
DailyMed Link:	PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE at DailyMed

US Patents and Regulatory Information for PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE	codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride	SYRUP;ORAL	040674-001	Dec 23, 2014		DISCN	No	No

Promethazine Hydrochloride, Phenylephrine Hydrochloride w/ Codeine Phosphate: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

The combination drug product containing Promethazine Hydrochloride, Phenylephrine Hydrochloride, and Codeine Phosphate is a multi-ingredient formulation primarily used for the relief of cough and cold symptoms. Market dynamics are shaped by factors including patent expiry, regulatory landscape, generic competition, and evolving treatment guidelines. Financial trajectory is intrinsically linked to sales volume, pricing strategies, and market share in both branded and generic segments.

What is the primary indication and mechanism of action for this combination product?

The combination product is indicated for the temporary relief of cough and runny nose due to the common cold, hay fever, or other upper respiratory allergies.

• Promethazine Hydrochloride: This is an antihistamine and antiemetic. It acts as a H1 receptor antagonist, blocking the action of histamine, a substance in the body that causes allergic symptoms. Its sedative properties contribute to symptom relief and potentially aid sleep during illness.
• Phenylephrine Hydrochloride: This is a decongestant. It acts as an alpha-adrenergic receptor agonist, causing vasoconstriction in the nasal mucosa, thereby reducing swelling and congestion.
• Codeine Phosphate: This is an opioid analgesic and antitussive. It acts centrally on the cough center in the brain to suppress the cough reflex. It also possesses mild analgesic properties.

The combination leverages these distinct mechanisms to address multiple symptoms associated with upper respiratory tract infections and allergies.

What is the current patent landscape for Promethazine Hydrochloride, Phenylephrine Hydrochloride w/ Codeine Phosphate?

The core patents covering the individual active pharmaceutical ingredients (APIs) have long expired. For instance, patents for promethazine hydrochloride date back to the mid-20th century, and similarly, phenylephrine hydrochloride and codeine phosphate have also been off-patent for decades.

The patent landscape for the specific combination product is more nuanced. While patents on individual APIs are expired, patents may have existed or still exist for:

• Specific formulations: This could include patents covering unique excipients, dosage forms (e.g., extended-release versions), or specific ratios of the APIs that offer an improved therapeutic profile or patient compliance.
• Manufacturing processes: Novel or improved methods of synthesizing or combining the APIs could have been patented.
• New indications or uses: While less common for such established APIs, patents could have been filed for specific therapeutic applications of the combination beyond its primary use.

As of the most recent patent filings and expirations, the primary patents protecting the original branded combination products have largely lapsed. This has opened the market to generic manufacturers. The average patent life for a drug is around 20 years from the filing date, but for many older drugs like those in this combination, patent protection has long since expired.

Who are the key market players and what is their market share?

The market for Promethazine Hydrochloride, Phenylephrine Hydrochloride w/ Codeine Phosphate is characterized by a significant presence of generic manufacturers, alongside some historical branded products. Due to the nature of generic drug markets, precise, real-time market share data for specific combination products can be difficult to ascertain publicly and often shifts based on pricing and distribution agreements.

Branded Product (Historically Significant):

• PHENERGAN® VC (with Codeine): This is a well-known branded product from Pfizer (originally Wyeth). While still available, its market share has been significantly impacted by generic competition.

Generic Manufacturers:

The market is highly fragmented with numerous generic pharmaceutical companies producing and distributing this combination. Key players include, but are not limited to:

• Teva Pharmaceuticals: A major global generic drug manufacturer.
• Mylan N.V. (now part of Viatris): Another significant player in the generic and specialty pharmaceutical space.
• Apotex Inc.: A Canadian pharmaceutical company with a broad generic portfolio.
• Prasco Laboratories: Specializes in the development and marketing of authorized generics.
• Various smaller and regional manufacturers: Numerous companies supply this product to specific markets or through private label agreements.

Market share is often determined by the ability to secure favorable contracts with large pharmacy chains, distributors, and government healthcare programs. Pricing competition among generic manufacturers is a dominant factor.

What are the regulatory considerations and recent policy changes affecting this product?

The regulatory landscape is crucial for this combination product, particularly concerning the inclusion of codeine, a controlled substance, and phenylephrine, which has faced recent scrutiny.

• Controlled Substance Status (Codeine): Codeine is a Schedule V controlled substance in the United States under the Controlled Substances Act. This classification requires specific prescribing and dispensing regulations, including prescription requirements and limitations on refills. State-level regulations can vary.
• Phenylephrine Efficacy and FDA Review: In late 2023, the U.S. Food and Drug Administration (FDA) convened an advisory committee to review the efficacy of oral phenylephrine as a decongestant. The committee unanimously concluded that oral phenylephrine is not effective for treating nasal congestion when used at the recommended dosage. This has led to potential regulatory actions, including a possible reclassification or removal of the drug from the market. The FDA has not yet issued a final decision or regulatory action. (Source: FDA Advisory Committee Meeting, November 2023)
• FDA Black Box Warnings: Products containing codeine, particularly those intended for pediatric use, have historically been subject to enhanced warnings regarding respiratory depression and the risk of misuse and addiction.
• DEA Scheduling: The Drug Enforcement Administration (DEA) monitors and schedules controlled substances. Changes to the scheduling of codeine or its precursors can impact availability and prescribing practices.

The potential regulatory reclassification or removal of phenylephrine from over-the-counter (OTC) status could significantly impact the market for this combination product, especially if it is primarily marketed as an OTC remedy. Manufacturers may need to reformulate products or face market withdrawal if the combination can no longer be deemed effective.

What is the historical and projected financial performance of this drug class?

The financial performance of Promethazine Hydrochloride, Phenylephrine Hydrochloride w/ Codeine Phosphate is best understood by examining trends in the broader cough and cold segment, influenced by patent expirations and genericization.

Historical Performance:

• Branded Dominance (Pre-Genericization): Branded products like PHENERGAN® VC enjoyed significant revenue during their patent-protected periods due to higher pricing power.
• Generic Entry and Price Erosion: Upon patent expiry, generic versions entered the market, leading to a dramatic decrease in average selling prices (ASPs) and a shift in revenue generation from branded manufacturers to generic producers.
• Market Size: The global cough and cold remedies market is substantial, valued at tens of billions of dollars annually. However, this specific combination's contribution is a segment within that larger market. Its sales have likely been relatively stable or declining in real terms due to increased competition and the availability of single-ingredient products.
• Opioid Scrutiny Impact: Increased public and regulatory attention on opioid use, including codeine, has led to more conservative prescribing practices and a potential reduction in demand for codeine-containing cough suppressants.

Projected Financial Trajectory:

The financial trajectory for this specific combination is subject to significant headwinds, primarily driven by the evolving regulatory stance on phenylephrine and the ongoing pressure from single-ingredient generics and alternative therapies.

• Declining Demand: If oral phenylephrine is deemed ineffective and removed from the market, formulations containing it will face significant obsolescence. This could lead to a sharp decline in sales for existing products.
• Continued Generic Price Competition: For any remaining formulations, the market will remain highly competitive, characterized by low margins and volume-driven sales for generic manufacturers.
• Shift to Alternatives: Patients and healthcare providers may increasingly opt for single-ingredient cough suppressants (e.g., dextromethorphan), antihistamines, or decongestants, or explore non-pharmacological remedies, further eroding demand for multi-symptom combination products.
• Regulatory Uncertainty: The outcome of the FDA's review of phenylephrine is a critical determinant of future financial performance. A negative outcome would severely curtail the market.
• Market Value Estimates: Precise current market value figures for this specific combination are not readily available as it is a mature product within a broad category. However, the trend for older, multi-API formulations facing such regulatory and competitive pressures is generally one of gradual decline or stagnation. The total market for cough and cold products remains robust, but this particular formulation's share is expected to shrink.

The financial future of this combination hinges heavily on regulatory decisions regarding phenylephrine. Without significant reformulation or a favorable regulatory outcome, its market presence and associated revenue are projected to diminish.

What are the key competitive pressures and market trends influencing this product?

The competitive landscape for Promethazine Hydrochloride, Phenylephrine Hydrochloride w/ Codeine Phosphate is shaped by several enduring and emerging trends.

• Generic Competition: As noted, the market is dominated by generic manufacturers. This leads to intense price wars, where the lowest cost producer often captures the largest volume. Manufacturers must optimize supply chains and production costs to remain competitive.
• Single-Ingredient Products: Consumers and healthcare providers often prefer single-ingredient products for targeted symptom relief. This allows for individualized dosing and avoids unnecessary exposure to ingredients. Examples include:
  • Antihistamines: Loratadine, Cetirizine, Fexofenadine.
  • Decongestants: Pseudoephedrine (though with its own regulatory challenges), Oxymetazoline nasal sprays.
  • Antitussives: Dextromethorphan.
• Therapeutic Guidelines and Prescriber Behavior: Evolving medical guidelines may shift away from multi-symptom formulations towards more targeted treatments. Prescribers may be more inclined to recommend separate medications based on specific diagnoses.
• Consumer Demand for "Natural" or "Non-Drowsy" Options: There is a growing consumer preference for products perceived as more natural or with fewer side effects, such as non-drowsy formulations and those free from codeine due to concerns about addiction and side effects.
• Regulatory Scrutiny of Ingredients: As highlighted with phenylephrine, increased regulatory examination of drug efficacy and safety can lead to market disruptions. The potential removal of phenylephrine would necessitate reformulation or market exit.
• Formulation Innovation (Limited for older drugs): While innovation is less likely for established generics, some companies may seek to differentiate through improved delivery systems or excipients, though the high volume, low-margin nature of this market limits significant R&D investment.
• Pharmacy Benefit Managers (PBMs) and Formulary Management: PBMs play a significant role in dictating which medications are covered and at what cost. Their formulary decisions, often favoring lower-cost generics, directly impact sales volumes and pricing.

The primary competitive pressure remains generic price erosion, exacerbated by the potential regulatory challenge to phenylephrine's efficacy, which could render a significant portion of existing products obsolete.

What are the risks and opportunities for stakeholders?

Stakeholders in Promethazine Hydrochloride, Phenylephrine Hydrochloride w/ Codeine Phosphate face a landscape of significant risks alongside limited, niche opportunities.

Risks:

• Regulatory Delisting/Reclassification of Phenylephrine: This is the most immediate and substantial risk. If oral phenylephrine is declared ineffective or removed from the market, current product formulations will become unsellable as marketed.
• Increased Scrutiny and Restrictions on Codeine: Ongoing concerns about opioid misuse could lead to further regulatory actions, such as stricter prescribing requirements, reduced refill allowances, or even down-scheduling, impacting demand and accessibility.
• Intensified Generic Price Erosion: The highly competitive generic market will continue to exert downward pressure on prices, squeezing profit margins for manufacturers and distributors.
• Competition from Single-Ingredient Drugs: The trend towards targeted therapies means consumers may increasingly opt for single-ingredient products, bypassing multi-symptom combinations.
• Declining Physician and Consumer Confidence: Negative publicity or regulatory actions can erode trust in the efficacy or safety of the combination.
• Supply Chain Vulnerabilities: Reliance on specific API suppliers or manufacturing sites can expose companies to disruptions.

Opportunities:

• Reformulation (Conditional): If phenylephrine is removed, there may be an opportunity to reformulate the product to include an alternative effective decongestant, provided it can be done economically and remains therapeutically justified. However, the development costs might outweigh the potential returns in this mature market.
• Authorized Generics: Manufacturers with established relationships can produce authorized generics for branded products, capturing a portion of that market.
• Niche Markets and Specific Geographies: In certain regions or for specific patient populations where regulatory hurdles are lower or alternative treatments are less accessible, demand may persist.
• Cost Leadership in Generic Manufacturing: Companies with highly efficient manufacturing and supply chain operations can still achieve profitability by capturing volume at the lowest cost.
• Distribution Partnerships: Securing exclusive or preferred distribution agreements with major pharmacy chains or healthcare systems can provide a stable sales channel.

The overriding factor for both risks and opportunities is the regulatory outcome concerning phenylephrine.

Key Takeaways

• The combination drug Promethazine Hydrochloride, Phenylephrine Hydrochloride w/ Codeine Phosphate faces significant market challenges driven by the expiration of core API patents and intense generic competition.
• Regulatory scrutiny is high, particularly concerning the efficacy of oral phenylephrine, which is currently under FDA review, posing a substantial risk of market withdrawal or reformulation requirements.
• Codeine's status as a controlled substance imposes regulatory burdens and contributes to declining prescribing trends due to opioid concerns.
• The market is dominated by generic manufacturers, leading to persistent price erosion and low margins.
• The financial trajectory is projected to be negative unless significant product reformulations address the regulatory challenges and competitive pressures from single-ingredient alternatives.

Frequently Asked Questions

1. What is the FDA's current stance on oral phenylephrine? The FDA's advisory committee has concluded that oral phenylephrine is not effective for nasal congestion at recommended doses. The agency has not yet issued a final regulatory decision.
2. Will Promethazine Hydrochloride, Phenylephrine Hydrochloride w/ Codeine Phosphate be removed from the market? A potential removal or reformulation is possible if the FDA takes regulatory action based on the review of phenylephrine's efficacy. The decision is pending.
3. How does the controlled substance status of codeine affect this product? Codeine's Schedule V classification requires prescriptions, limits refills, and necessitates adherence to DEA regulations, impacting prescribing patterns and accessibility.
4. Are there any branded versions of this combination still widely prescribed? While historically significant products exist, such as PHENERGAN® VC with Codeine, their market share has been substantially eroded by generic competition.
5. What are the main alternatives to this combination product? Alternatives include single-ingredient antihistamines, decongestants, and antitussives, as well as products containing dextromethorphan.

Citations

[1] U.S. Food and Drug Administration. (2023, November). FDA Advisory Committee Meeting Materials: Nonprescription Drugs Advisory Committee Meeting. Retrieved from [Relevant FDA Meeting Page - Placeholder, actual link would be specific] [2] Controlled Substances Act, 21 U.S.C. § 801 et seq. (1970). [3] Drug Enforcement Administration. (n.d.). Schedules of Controlled Substances. Retrieved from [Relevant DEA Scheduling Page - Placeholder, actual link would be specific] [4] Pfizer Inc. (Annual Reports and Product Information - Historical). Company filings and product information for Phenergan VC with Codeine. (Specific document references vary by year and filing). [5] Global Market Research Reports on Cough and Cold Remedies. (Various Publishers and Dates). Market Analysis and Forecasts for the Cough and Cold Segment. (Specific reports are proprietary and numerous).